July 2, 2004 — Continuous subcutaneous insulin infusion (CSII) improved glycemic control in children and adolescents with type 1 diabetes better than did multiple daily injection (MDI) with glargine, ...

This new study investigated and compared the incidence of disordered eating behavior (DEB) among 2 cohorts of patients with type 1 diabetes (T1D) treated with continuous-subcutaneous insulin infusion ...

Hoogma RPLM et al. (2005) Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: ...

The Diabetes Control and Complications Trial research group documented that low glycosylated hemoglobin (HbA1c) levels were associated with reduced onset and progression of microvascular complications ...

A review of published research from the University of Liege, Belgium, reveals a decline in the number of people experiencing allergic reactions to insulin. This is largely due to better purification ...

The effect of switching from multiple daily insulin injections to an insulin pump on insulin and other diabetic drug expenditures in type 2 diabetes. Continuous users of MDI therapy throughout the ...

HealthDay News — For patients with type 2 diabetes and hemoglobin A1c (HbA1c) >8% following multiple daily injections (MDI), continuous subcutaneous insulin infusion (CSII) is associated with a ...

The expanded approval was based on data from the phase 3 PRONTO-PUMP-2 trial which evaluated Lyumjev vs Humalog for use in insulin pump therapy in 432 adults with type 1 diabetes. The Food and Drug ...

Subcutaneous insulin infusion (CSII) is the gold standard for type 1 diabetic patient therapy. Less physiological than intraperitoneal administration, the subcutaneous route may induce glycemic ...

Insulin pumps decrease mortality, cardiovascular disease risk Compared with multiple daily injections, patients who used continuous subcutaneous insulin infusion (CSII) had a lower likelihood of ...